Affiliation:
1. Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
Abstract
The great clinical success of chimeric antigen receptor T cell (CAR-T) and PD-1/PDL-1 inhibitor
therapies suggests the drawing of a cancer immunotherapy age. However, a considerable proportion
of cancer patients currently receive little benefit from these treatment modalities, indicating that
multiple immunosuppressive mechanisms exist in the tumor microenvironment. In this review, we
mainly discuss recent advances in small molecular regulators targeting G Protein-Coupled Receptors
(GPCRs) that are associated with oncology immunomodulation, including chemokine receptors,
purinergic receptors, prostaglandin E receptor EP4 and opioid receptors. Moreover, we outline how they
affect tumor immunity and neoplasia by regulating immune cell recruitment and modulating tumor
stromal cell biology. We also summarize the data from recent clinical advances in small molecular regulators
targeting these GPCRs, in combination with immune checkpoints blockers, such as PD-1/PDL-1
and CTLA4 inhibitors, for cancer treatments.
Funder
Innovation Program of Shanghai Municipal Education Commission
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Reference174 articles.
1. Liu Y.; An S.; Ward R.; Yang Y.; Guo X.X.; Li W.; Xu T.R.; G protein-coupled receptors as promising cancer targets. Cancer Lett 2016,376(2),226-239
2. Sunshine J.; Taube J.M.; PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015,23,32-38
3. Raedler L.A.; Opdivo (Nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits, (Spec Feature)2015,8,180-183
4. Porter D.L.; Hwang W-T.; Frey N.V.; Lacey S.F.; Shaw P.A.; Loren A.W.; Bagg A.; Marcucci K.T.; Shen A.; Gonzalez V.; Ambrose D.; Grupp S.A.; Chew A.; Zheng Z.; Milone M.C.; Levine B.L.; Melenhorst J.J.; June C.H.; Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015,7(303),303
5. Schumacher T.N.; Schreiber R.D.; Neoantigens in cancer immunotherapy. Science 2015,348(6230),69-74
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献